Research Article

Development and validation of a m⁶A-related gene signature for predicting the prognosis of hepatocellular carcinoma

Department of Emergency Surgery, Department of Emergency Medicine, The First affiliated hospital of Anhui Medical University, Heifei 230022, China

‡Authors contributed equally

Search for more papers by this author

Xutong Li‡

Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

‡Authors contributed equally

Search for more papers by this author

Honghai Xu

Department of Pathology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

Search for more papers by this author

Yufeng Gao

*Author for correspondence: Tel.: +86 139 56 93 8032;

E-mail Address: gaoyufeng121212@163.com

https://orcid.org/0000-0003-0032-3531

Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China

Search for more papers by this author

Published Online:6 Oct 2020https://doi.org/10.2217/bmm-2020-0178

View article

Abstract

Background: This study aimed to investigate the prognostic role of m⁶A methylation regulators in hepatocellular carcinoma (HCC). Materials & methods: Gene expression matrices were downloaded from The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium, and Gene Expression Omnibus databases. Univariate and multivariate regression analysis were utilized to determine the m⁶A risk genes. Results: Two m⁶A-related risk genes (YTHDF1, YTHDF2) were identified in the TCGA HCC cohort. The m⁶A-correlated risk score is an independent risk factor for the overall survival of the TCGA HCC cohort. Finally, we verified the reliability of our results using three external datasets. Conclusion: The m⁶A-correlated gene signature has prognostic value in HCC patients and thus provides guidance for the treatment of HCC.

Keywords:

Reference

1. Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J. Gastroenterol. 21(42), 12003–12021 (2015).Crossref, Medline, CAS, Google Scholar
2. Umeda S, Kanda M. Recent advances in molecular biomarkers for patients with hepatocellular carcinoma Expert Rev Mol Diagn 19(8), 725–738 (2019).Crossref, Medline, CAS, Google Scholar
3. Bangaru S, Marrero JA, Singal AG. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Aliment Pharmacol Ther 51(1), 78–89 (2020).Crossref, Medline, CAS, Google Scholar
4. Li Y, Xiao J, Bai J et al. Molecular characterization and clinical relevance of m(6)A regulators across 33 cancer types. Mol. Cancer 18(1), 137 (2019).Crossref, Medline, Google Scholar
5. He L, Li H, Wu A, Peng Y, Shu G, Yin G. Functions of N6-methyladenosine and its role in cancer. Obes. Rev. 18(1), 176 (2019).Google Scholar
6. Livneh I, Moshitch-Moshkovitz S, Amariglio N, Rechavi G, Dominissini D. The m(6)A epitranscriptome: transcriptome plasticity in brain development and function. Nat Rev Neurosci 21(1), 36–51 (2020).Crossref, Medline, CAS, Google Scholar
7. Wu J. Emerging role of m(6) A RNA methylation in nutritional physiology and metabolism. Nat. Rev. Neurosci. 21(1), e12942 (2020).CAS, Google Scholar
8. Zhou Y, Huang T, Siu HL et al. IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis. Mol. Cancer 16(1), 77 (2017).Crossref, Medline, Google Scholar
9. Cai J, Yang F. RNA m(6)A methyltransferase METTL3 promotes the growth of prostate cancer by regulating hedgehog pathway. Onco Targets Ther 12, 9143–9152 (2019).Crossref, Medline, CAS, Google Scholar
10. Chen Y, Peng C, Chen J et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Mol. Cancer 18(1), 127 (2019).Crossref, Medline, Google Scholar
11. Cheng M, Sheng L, Gao Q et al. The m(6)A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-kappaB/MYC signaling network. Oncogene 38(19), 3667–3680 (2019).Crossref, Medline, CAS, Google Scholar
12. Li J, Han Y, Zhang H et al. The m6A demethylase FTO promotes the growth of lung cancer cells by regulating the m6A level of USP7 mRNA. Mol. Cancer 512(3), 479–485 (2019).CAS, Google Scholar
13. Li T, Hu PS, Zuo Z et al. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer 18(1), 112 (2019).Crossref, Medline, Google Scholar
14. Miao W, Chen J, Jia L, Ma J, Song D. The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1. Biochem. Biophys. Res. Commun. 516(3), 719–725 (2019).Crossref, Medline, CAS, Google Scholar
15. Qian JY, Gao J, Sun X et al. KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner. Oncogene 38(33), 6123–6141 (2019).Crossref, Medline, CAS, Google Scholar
16. Zhan H, Situ J, Li W et al. The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion. Onco. Targets Ther. 215(11), 152666 (2019).Google Scholar
17. Zhou R, Gao Y, Lv D, Wang C, Wang D, Li Q. METTL3 mediated m(6)A modification plays an oncogenic role in cutaneous squamous cell carcinoma by regulating DeltaNp63. Biochem. Biophys. Res. Commun. 515(2), 310–317 (2019).Crossref, Medline, CAS, Google Scholar
18. Zou D, Dong L, Li C, Yin Z, Rao S, Zhou Q. The m(6)A eraser FTO facilitates proliferation and migration of human cervical cancer cells. Cancer Cell Int. 19, 321 (2019).Crossref, Medline, CAS, Google Scholar
19. Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu. Rev. Pathol. 13, 395–412 (2018).Crossref, Medline, CAS, Google Scholar
20. Toh TB, Lim JJ, Chow EK. Epigenetics of hepatocellular carcinoma. Clin. Transl. Med. 8(1), 13 (2019).Crossref, Medline, Google Scholar
21. Shi Y, Fan S, Wu M, Zuo Z. YTHDF1 links hypoxia adaptation and non-small-cell lung cancer progression. Nat Commun 10(1), 4892 (2019).Crossref, Medline, CAS, Google Scholar
22. Yang C, Chen Y, Bai Y et al. YTHDF1 regulates tumorigenicity and cancer stem cell-like activity in human colorectal carcinoma. Front Oncol. 9, 332 (2019).Crossref, Medline, Google Scholar
23. Lin X, Chai G, Wu Y, Li J, Chen F, Liu J. RNA m(6)A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of snail. Nat Commun 10(1), 2065 (2019).Crossref, Medline, Google Scholar
24. Zhou Y, Yin Z, Hou B et al. Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets. Cancer Manag. Res. 11, 3921–3931 (2019).Crossref, Medline, CAS, Google Scholar
25. Chen J, Sun Y, Xu X et al. YTH domain family 2 orchestrates epithelial-mesenchymal transition/proliferation dichotomy in pancreatic cancer cells. Cell Cycle 16(23), 2259–2271 (2017).Crossref, Medline, CAS, Google Scholar
26. Yang Z, Li J, Feng G et al. MicroRNA-145 modulates N(6)-methyladenosine levels by targeting the 3′-untranslated mRNA region of the N(6)-methyladenosine binding YTH domain family 2 protein. J. Biol. Chem. 292(9), 3614–3623 (2017).Crossref, Medline, CAS, Google Scholar
27. Li J, Meng S, Xu M et al. Downregulation of N(6)-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N(6)-methyladenosine levels. Oncotarget 9(3), 3752–3764 (2018).Crossref, Medline, Google Scholar
28. Xie L, Sheng H, Li Z et al. YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation. J. Cell Mol. Med. doi:10.1111/jcmm.15063 (2019) (Epub ahead of print).Google Scholar
29. Xie H, Li J, Ying Y et al. METTL3/YTHDF2 m(6) A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer. doi:10.1111/jcmm.15063 (2020) (Epub ahead of print).Crossref, Google Scholar
30. Sheng H, Li Z, Su S et al. YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation. Carcinogenesis doi:10.1093/carcin/bgz152 (2019) (Epub ahead of print).Google Scholar
31. Chen M, Wei L, Law CT et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology 67(6), 2254–2270 (2018).Crossref, Medline, CAS, Google Scholar

Vol. 14, No. 13

Metrics

Downloaded 140 times

History

Received 27 March 2020

Accepted 12 June 2020

Published online 6 October 2020

Published in print September 2020

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/bmm-2020-0178

Acknowledgments

The authors sincerely thank TCGA, ICGC, Gene expression omnibus and cBioPortal provide the detailed information.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download

Development and validation of a m6A-related gene signature for predicting the prognosis of hepatocellular carcinoma

Abstract

Reference

Development and validation of a m⁶A-related gene signature for predicting the prognosis of hepatocellular carcinoma